Medical devices, healthcare technology and the business of care
PMA approval · P100044

PROPEL

Intersect Ent. · Decision date Aug 11, 2011

MEDTECHLEDGER EXPLANATIONP100044

What did the FDA approve?

The FDA approved the PROPEL sinus implant for patients 18 years and older after ethmoid sinus surgery. The stated purpose is to maintain patency and reduce the need for post-operative intervention such as surgical adhesion lysis or oral steroid use.

The device is described as separating mucosal tissues, stabilizing the middle turbinate, preventing obstruction by adhesions, and reducing edema. The source statement reports these intended functions but does not provide independent proof of safety or clinical effectiveness. No supplement type or reason is recorded.

FDA approval order statement

APPROVAL FOR THE PROPEL SINUS IMPLANT. THIS DEVICE IS INDICATED FOR USE IN PATIENTS >= 18 YEARS OF AGE FOLLOWING ETHMOID SINUS SURGERY TO MAINTAIN PATENCY, THEREBY REDUCING THE NEED FOR POST-OPERATIVE INTERVENTION SUCH AS SURGICAL ADHESION LYSIS AND/OR USE OF ORAL STEROIDS. THE PROPEL SINUS IMPLANT SEPARATES MUCOSAL TISSUES, PROVIDES STABILIZATION OF THE MIDDLE TURBINATE, PREVENTS OBSTRUCTION BY ADHESIONS, AND REDUCES EDEMA.
Regulatory pathway
Original PMA
Clinical specialty
Ear, Nose, Throat
Decision date
Aug 11, 2011

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P100044
Regulatory pathway
Premarket approval application
Product code
OWO
Decision code
APPR
Decision date
Aug 11, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting sinus stent.

Product code
OWO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P100044 received

    Application receipt date recorded by FDA.

  2. P100044 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100044

Product / regulatory recordCompanyPathwayDecision dateSource
PROPELP100044/S061
Intersect Ent.PMA supplementSep 22, 2026FDA
Intersect Ent.PMA supplementSep 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Intersect Ent.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1555 Adams Dr., Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records